CD8A and hepatocellular carcinoma: In vivo blockade of NETs using PAD4-/- mice or DNase I treatment attenuates the Treg activity and augments cytotoxic CD4+ and CD8+ T-cell function, thus mitigating MASH-HCC initiation and development.